Abstract
Naming impairment in Alzheimer’s disease dementia (AD) is associated with atrophy of the left anterior temporal lobe (ATL). We aimed to elucidate if regional cerebral glucose metabolism, as a biomarker of synaptic dysfunction and neurodegeneration, of the left ATL predicts naming impairment, and if amyloid-beta (Aβ) deposition, a pathological hallmark of AD, contributes to the prediction.
Twenty-nine patients with AD underwent combined [11C]PIB and [18F]FDG PET examinations for assessment of Aβ load and regional cerebral glucose metabolism. An a priori defined region of interest was used for regional PET analyses of the left ATL. In linear stepwise regression analyses, glucose metabolism of the left ATL was the only significant predictor of naming performance, independent of sex, age, and education. Neither regional nor global Aβ load contributed to the prediction.
Left ATL glucose metabolism predicts naming impairment in AD. By contrast, Aβ deposition does not predict naming impairment.
Keywords: Alzheimer’s disease, amyloid, confrontation naming, Pittsburgh compound B, positron emission tomography.
Current Alzheimer Research
Title:Left Anterior Temporal Glucose Metabolism and not Amyloid-beta Load Predicts Naming Impairment in Alzheimer’s Disease
Volume: 13 Issue: 6
Author(s): Lars Frings, Timo S. Spehl, Michael Hüll and Philipp T. Meyer
Affiliation:
Keywords: Alzheimer’s disease, amyloid, confrontation naming, Pittsburgh compound B, positron emission tomography.
Abstract: Naming impairment in Alzheimer’s disease dementia (AD) is associated with atrophy of the left anterior temporal lobe (ATL). We aimed to elucidate if regional cerebral glucose metabolism, as a biomarker of synaptic dysfunction and neurodegeneration, of the left ATL predicts naming impairment, and if amyloid-beta (Aβ) deposition, a pathological hallmark of AD, contributes to the prediction.
Twenty-nine patients with AD underwent combined [11C]PIB and [18F]FDG PET examinations for assessment of Aβ load and regional cerebral glucose metabolism. An a priori defined region of interest was used for regional PET analyses of the left ATL. In linear stepwise regression analyses, glucose metabolism of the left ATL was the only significant predictor of naming performance, independent of sex, age, and education. Neither regional nor global Aβ load contributed to the prediction.
Left ATL glucose metabolism predicts naming impairment in AD. By contrast, Aβ deposition does not predict naming impairment.
Export Options
About this article
Cite this article as:
Frings Lars, Spehl S. Timo, Hüll Michael and Meyer T. Philipp, Left Anterior Temporal Glucose Metabolism and not Amyloid-beta Load Predicts Naming Impairment in Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160322141955
DOI https://dx.doi.org/10.2174/1567205013666160322141955 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enriched Environment Prevents Cognitive Impairment and Tau hyperphosphorylation after Chronic Cerebral Hypoperfusion
Current Neurovascular Research Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimer’s Disease Patients vs. Drug Treated Parkinson’s Disease Patients vs. Age-matched Normal Controls
Current Alzheimer Research Assessing Depression in Patients with an Acute Coronary Syndrome: A Literature Review
Current Psychiatry Reviews Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Diabetes and Periodontal Diseases: Interplay and Links
Current Diabetes Reviews Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry 5-ht6 Receptors
Current Drug Targets - CNS & Neurological Disorders Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Inhibition of GSK3 Dependent Tau Phosphorylation by Metals
Current Alzheimer Research Patenting Penicillium Strains
Recent Patents on Biotechnology Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design BACE Inhibitors as Potential Therapeutics for Alzheimers disease
Recent Patents on CNS Drug Discovery (Discontinued) Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Neuropsychological Aspects of Dual Diagnosis
Current Drug Abuse Reviews